A Prospective Observational Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus Clinical Trial

Official title:

A Prospective, Single Center, Post-Market Observational Study to Assess the Efficacy, Safety, and Patient Reported Outcomes of Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02158078
• Other study ID #: CQR13002
• Status: Terminated
• Phase: N/A
• First received: June 4, 2014
• Last updated: July 25, 2016
• Start date: June 2014
• Est. completion date: November 2014

Study information

• Verified date: July 2016
• Source: CeQur Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: Austria: Austrian Medicines and Medical Devices Agency
• Study type: Observational

Clinical Trial Summary

The purpose of the study is to obtain an assessment (efficacy, safety, and patient reported outcomes) of basal bolus insulin delivery with PaQ in insulin-using patients with type 2 diabetes mellitus (T2DM).

Description:

This is a prospective, single center, post-market observational study to assess the efficacy, safety, and patient reported outcomes of insulin delivery with PaQ® in patients with type 2 diabetes mellitus (T2DM) who are currently receiving basal/bolus insulin therapy with or without oral anti-diabetic drugs (OADs) for glycemic control. The patient's participation in the study is comprised of three phases: screening/baseline evaluation, transition to PaQ use and optimization, and PaQ treatment period. The use of these phases will allow an orderly transition to PaQ treatment as well as a reliable construct from which to interpret the final data.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: November 2014
• Est. primary completion date: November 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Is at least 18 years of age

• Has a clinical diagnosis of T2DM, as determined by clinical history and medication usage

• Has an A1C = 7.0% and = 11.0%;

• Is treated with basal-bolus insulin therapy (at least 2 injections per day) with or without OADs, and/or glucagon-like peptide-1 (GLP-1) agonist for at least 3 months and has not had a change (addition or discontinuation of existing drug or change in dose) in their OADs for the last 8 weeks

• Determined by the investigator that insulin requirements to achieve glycemic targets can be met by the insulin capacity of the PaQ device

• If on concomitant metformin, has serum creatinine <1.5 mg/dL (male) or <1.4 mg/dL (female)

• If female, and of child-bearing potential, has a negative urine pregnancy test at screening and must be using adequate means of contraception as determined by the Investigator

• Is clinically euthyroid as judged by the Investigator

• Is able to understand and sign the required study documents and comply with the clinical investigational plan (CIP) requirements

• Is deemed capable by the Investigator to perform the requirements of the CIP, including use of PaQ, frequent self-monitoring of blood glucose

Exclusion Criteria:

• Is poorly compliant with the currently prescribed diabetes regimen, as determined by the Investigator

• Is poorly compliant with prescribed self-monitoring of blood glucose, as determined by the Investigator

• Is currently taking or has taken sulfonylureas within the last 2 months

• Has a BMI greater than 40 kg/m2

• Has experienced recurrent severe hypoglycemia (> 2 episodes) requiring assistance during the past 6 months

• Has existing dermal irritation/inflammation over the abdominal area that may interfere with use of PaQ, as determined by the Investigator

• Has known clinically significant hypersensitivity to skin adhesives

• Is female and if of child-bearing potential, is pregnant, lactating, or planning to become pregnant

• Is currently being treated with or expected to require or undergo treatment with systemic steroids by oral, intravenous, or intramuscular route (inhaled with low systemic exposure is permitted)

• Currently abuses drugs or alcohol or has a history of abuse that in the Investigator's opinion would cause the individual to be non-compliant

• Has received any investigational drug within 1 month

• Has donated blood within 30 days

• Has any significant medical condition (including current or past history of cardiovascular disease), laboratory findings, or medical history that in the Investigator's opinion may affect successful completion of the study and/or personal well-being

• Is an immediate family member (spouse, parent, child, or sibling) of personnel directly affiliated with the study at the investigative site, or is personally directly affiliated with the study at the investigative site

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus

Intervention

Device:
• PaQ® Insulin Delivery Device
PaQ is a 3 day insulin delivery device. Utilizes U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.

Locations

Country	Name	City	State
Austria	Medical University of Graz	Graz

Sponsors (1)

Lead Sponsor	Collaborator
CeQur Corporation

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in glycosylated hemoglobin A1C (HbA1c) (obtained from venous blood) from baseline at Week 12		12 weeks	No
Secondary	Change in A1C from baseline at Week 8		8 weeks	No
Secondary	Change in fasting plasma glucose from baseline at end of study week 12		12 weeks	No
Secondary	Change in 7-point blood glucose profiles and 1.5-2 hour postprandial blood glucose excursions (average and by meal) from baseline at week 12		12 weeks	No
Secondary	Change in insulin dose (total, basal, and bolus) from Baseline at week 12		12 weeks	No
Secondary	Change in body weight from baseline at Week 12		12 weeks	No
Secondary	Occurrence of hypoglycemia, adverse events, and/or dermal irritation at PaQ application site		Throughout the study	No
Secondary	Change in measures of PROs from baseline at Week 12		12 weeks	No